Epilepsy Drug During Pregnancy Linked To Autism

Expectant mothers who take the popular anti-epileptic drug valproate during pregnancy should be aware that there is an increased risk for their child developing autism compared with children of women who did not take the epilepsy drug, according to a recently published Danish study.

Valproate is a drug used for the treatment of epilepsy and other neuropsychological disorders. Maternal use during pregnancy was associated with a significantly increased risk of autism in offspring, according to a study in the April 24 issue of JAMA.

The population-based study included all children born alive in Denmark from 1996 to 2006. National registers were used to identify children exposed to valproate during pregnancy and diagnosed with autism spectrum disorders, (childhood autism [autistic disorder], Asperger syndrome, atypical autism, and other or unspecified pervasive developmental disorders).

The study involved data on 655,615 children born to 428,407 mothers between 1996 and 2006, including 508 children exposed to valproate during pregnancy. Over follow-up to a mean age of 8.8 years, 5,437 children were diagnosed with autism spectrum disorder, including 2,067 with childhood autism.

Data were analyzed and adjusted for potential factors that could have influenced the outcomes; such as maternal age at conception, paternal age at conception, parental psychiatric history, gestational age, birth weight, sex, congenital malformations, and parity. Children were followed up from birth until the day of autism spectrum disorder diagnosis, death, emigration, or December 31, 2010, whichever came first.

Among children exposed to valproate, the risk for autism spectrum disorder was 2.9-fold greater, and the risk for childhood autism was 5.1-fold greater than among unexposed children (absolute 14-year risk: 4.4 vs 1.5%; 2.5 vs 0.5%, respectively).

The risks for autism spectrum disorder and childhood autism were also 2.2-fold, and 5.6-fold greater, respectively, in exposed children than in children of mothers who stopped taking valproate at least 30 days before conception.

Writing in JAMA, the study authors stress that it is important to carefully balance these concerns against the benefits of valproate in epilepsy control.

Jakob Christensen, Ph.D., of Aarhus University Hospital, Aarhus, Denmark, and colleagues evaluated the association between maternal use of valproate during pregnancy and the risk of autism spectrum disorder and childhood autism in offspring.

“Because autism spectrum disorders are serious conditions with life-long implications for affected children and their families, even a moderate increase in risk may have major health importance,” said Christensen and colleagues.

“Still, the absolute risk of autism spectrum disorder was less than 5%, which is important to take into account when counseling women about the use of valproate in pregnancy.”

However, in an accompanying editorial, Kimford Meador and David Loring, both from Emory University in Atlanta, Georgia, USA, say that current rates of valproate prescriptions among girls and women of reproductive age indicate that the risks of fetal exposure are not sufficiently taken into account.

“This raises concern as to whether these women are receiving adequate information for informed consent based on a full understanding of the treatment risks and alternative therapies,” they write.

Alternative medications should be used wherever possible, and women should be informed of the risks associated with valproate even if they are not currently planning to conceive, they conclude.

Anti-epileptic drug exposure during pregnancy has been associated with an increased risk for congenital malformations and delayed cognitive development in the offspring, but little is known about the risk of other serious neuropsychiatric disorders,” according to background information in the article.

The authors caution that these findings must be balanced against the treatment benefits for women who require valproate for epilepsy control.



, , , , , ,

No comments yet.

Leave a Reply

GET HELP NOW!
  • This field is for validation purposes and should be left unchanged.
Latest Drug Injury News

Merck’s Falsification of Vaccine Data Exposed

Merk’s dirty little secret has been exposed. A pair of lawsuits, one filed by former employees of Merck and the other by doctors, alleged the company knew its mumps vaccine was less effective than the supposed 95 percent efficiency level. According to court documents the former virologists employed by Merck filed a whistleblower lawsuit four […]

Testosterone Therapy Linked To Heart-Attack, Stroke and Death

Millions of men have turned to testosterone therapy to treat symptoms of aging. However, they may not be aware that they are putting themselves at risk for heart attack or stroke. According to the latest study published in the journal PLOS ONE, researchers report that within 90 days of taking the hormone the risk of […]

What Is Doribax?

According to the FDA the antibacterial drug Doribax, that has been used to treat patients who develop pneumonia on ventilators, carries an increased risk of death and has a lower clinical cure rate by injection compared a similar drug known as Primaxin. What is Doribax? Doribax is an antibiotic that fights serious infections caused by […]

Is Using Tylenol or Ibuprofen During Pregnancy linked to ADHD?

What is a mother to do if she becomes ill during pregnancy?  The risks of consuming common drugs when pregnant are complex.  Although many doctors assure mothers that taking Tylenol is safe, a recent study by JAMA Pediatrics suggests otherwise.  The study found that mothers who used Tylenol for fever reduction while pregnant reported greater […]

Paxil Linked To Breast Cancer

City of Hope Cancer researchers indicate that a new test called the AroER Tri-Screen, desgined to look for drug side effects that could cause cancer, found a potential link between Paxil and breast cancer.  Paxil is a widely prescribed anti depressant. Research Researchers have found that Paxil has a weak estrogen effect that could increase […]

Latest Medical Device Injury News

Report Raises Concerns Over Heart Defibrillator Leads

The Food and Drug Administration (FDA) has just announced that they received a report that a St. Jude Durata cardiac defibrillator lead conductor became externalized; meaning the wire carrying electricity from the heart defibrillator to the heart was exposed through its insulation, a potentially dangerous and life-threatening defect.

HeartSine Class 1 Defibrillator Recall

HeartSine sent out a letter to customers in September, warning that the defibrillators may intermittently turn on and off, eventually depleting the battery.

FDA Medical Device Approval Based On Little Evidence

More than half of the high-risk cardiovascular devices approved in the past decade had no supporting active control data.

St. Jude Medical Gets FDA Warning

St. Jude Medical Inc. said it received a FDA warning about manufacturing and quality-control problems at its Sylmar, California, plant.

Hospira Still Facing Manufacturing And Regulatory Issues

Hospira has sent out 11 device notifications so far in 2013, including recall and device corrections. The company also said it sent notices to customers about some of its infusion pumps that had to either be recalled, fixed or adjusted.